«ОЦЕНКА ЦЕНТРАЛЬНОЙ ГЕМОДИНАМИКИ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА C И БЕЗ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ ДО РЕВАСКУЛЯРИЗАЦИИ СОСУДОВ СЕРДЦА»
Keywords:
diabetes mellitus 2 type 2, heart failure, left ventricular ejection fraction, galectin3Abstract
The purpose of the study is to study the state of central hemodynamics in patients with CHF with and without DM2 in comparison with other indicators.
Material and research methods. 65 patients with DM 2 and chronic heart failure (CHF) were examined (prospectively) in the period 2021-2022 in the Acad surgery center. V.V. Vakhidov on the basis of a scientific agreement together with the RSSPMCE PHM RUZ named after Acad. Yo.Kh. Turakulov. All observed patients were divided into 2 groups:
1 gr. - 34 patients with heart failure and DM2 subjected to AKSh
2 gr. - 31 patients with heart failure without DM2 subjected to AKSh
The control group will be 20 healthy persons.
To characterize the examined patients will be used: general clinical, biochemical and instrumental examinations.
Results. , In patients with heart failure without DM2, the level of blood glucose and the noma index were reliably lower in comparison with patients with DM2 +CHF. The average value of BMI in groups differed slightly, but between the CHF and DM2+ CHF group, the difference was statistically reliable.
Conclusions. In patients of the DM2 + CHF group and CHF reliable differences in the average indicators of age, BMI, glycemia, the values of insulin, and the Homa index were not found depending on the values of the left ventricular emission faction. At the same time, the reliability of the differences was revealed only according to Galelectin 3: these values increased significantly as FV decreased in patients with diabetes + CHA. (p <0.05).
References
Курята А.В, Ю.С. КушнирУровень и динамика Галектина-3 при хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка на фоне использования петлевых диуретиков // https://www.webcardio.org/urovenj-y-dynamyka-ghalektyna-3-pry-khronycheskoj-serdechnoj-nedostatochnosty-s-sokhranennoj-systolycheskoj-funktsyej-levogho-zheludochka-na-fone-yspoljzovanyya-petlevykh-dyuretykov.aspx
Щукин Ю. В. н, И. И. Березин, Е. А. Медведева, Е. И. Селезнев, В. А. Дьячков, Л. Н. Слатова.О значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительно-нитрозилирующего стресса у больных хронической сердечной недостаточностьюhttps://doi.org/10.15829/1560-4071-2013-2-45-49
Целуйко В.И.(1), Лозовая Т.А.(2), Сасюк О.С.(2)ГАЛЕКТИН-3 КАК ФАКТОР РИСКА неблагоприятных сердечно-сосудистых событий при долгосрочном наблюдении у больных с инфарктом миокарда правого желудочка на фоне q-инфаркта миокарда задней стенки левого желудочка //журнал «медицина неотложных состояний» 6 (69) 2015 http://www.mif-ua.com/archive/article/42272
Abuelo G. J. Normotensive Ischemic Acute Renal Failure / G. J. Abuelo // N. Engl. J. Med. - 2007. - № 357. - P. 797 - 805.
Biscetti Federico, Elisabetta Nardella,2 Maria Margherita Rando,2 Andrea Leonardo Cecchini,2Et all.Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study//Cardiovasc Diabetol. 2020; 19: 170.Published online 2020 Oct 7. doi: 10.1186/s12933-020-01151-z
Capell Warren H , Marc P Bonaca , Mark R Nehler , Edmond Chen , et all.Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) //Am Heart J. 2018 May;199:83-91. doi: 10.1016/j.ahj.2018.01.011. Epub 2018 Feb 3.
Garg Aakash , Deepti Virmani, Sahil Agrawal, Chirag Agarwal, et all.Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review //Cardiology. 2017;136(3):192-203. doi: 10.1159/000450573. Epub 2016 Oct 27.
Eijgelaar W. J. [et al The vulnerable patient: refocusing on the plaque? ] // Thromb. Haemost. - 2009. -Vol. 102. - P. 231-239.
Jozine M. [et al.] Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation // Eur. J. Heart Failure. - 2016. - Vol. 18. - P. 588 - 598.
Jude E B 1, S O Oyibo, N Chalmers, A J BoultonPeripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome //Diabetes Care. 2001 Aug;24(8):1433-7. doi: 10.2337/diacare.24.8.1433.
Kramer Frank, Hani N Sabbah , James J Januzzi , Faiez Zannad et all.Redefining the role of biomarkers in heart failure trials: expert consensus document //Heart Fail Rev. 2017 May;22(3):263-277. doi: 10.1007/s10741-017-9608-5.
Khan Shahzad , Sahibzada Tasleem Rasoo.l Current use of cardiac biomarkers in various heart conditions //Endocr Metab Immune Disord Drug Targets. 2020 Aug 31. doi: 10.2174/1871530320999200831171748. Online ahead of print.
Lichtenauer Michael, Peter Jirak , Bernhard Wernly, Vera Paar , et all. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure// Eur J Intern Med. 2017 Oct;44:31-38. doi: 10.1016/j.ejim.2017.05.027. Epub 2017 Jun 1.
Murtaza Ghulam , Hafeez Ul Hassan Virk , Muhammad Khalid , Carl J Lavie , et all. Diabetic cardiomyopathy - A comprehensive updated review// Prog Cardiovasc Dis. Jul-Aug 2019;62(4):315-326.doi: 10.1016/j.pcad.2019.03.003. Epub 2019 Mar 25.
Piek Arnold, Weijie Du , Rudolf A de Boer , Herman H W Silljé .Novel heart failure biomarkers: why do we fail to exploit their potential? //Crit Rev Clin Lab Sci. 2018 Jun;55(4):246-263. doi: 10.1080/10408363.2018.1460576. Epub 2018 Apr 17.
Regitz-Zagrosek V. [et al.] Effects of female sex and age on early mortality in aortocoronary bypass surgery // Eur. Heart J. - 2004. - Vol. 25. - P. 134 - 142.
Reynolds H. R. [et al.] Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease // Circulation. -2011. - Vol. 124. - P. 1414 - 1425.
Stone Patrick Alan , Stephanie N Thompson , Mija Khan , Elizabeth Northfield .The Impact of Biochemical Markers on Major Adverse Cardiovascular Events and Contralateral Carotid Artery Stenosis Progression Following Carotid Interventions //Ann Vasc Surg. 2017 Jan;38:144-150. doi: 10.1016/j.avsg.2016.08.004. Epub 2016 Aug 19.
Shammas Andrew N, Haekyung Jeon-Slaughter , Shirling Tsai , Houman Khalili et all.Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus// J Endovasc Ther. 2017 Jun;24(3):376-382. doi: 10.1177/1526602817705135. Epub 2017 Apr 25.
Sarhene Michael, Yili Wang , Jing Wei , Yuting Huang , et all. Biomarkers in heart failure: the past, current and future //Heart Fail Rev. 2019 Nov;24(6):867-903. doi: 10.1007/s10741-019-09807-z.
Vupputuri Anjith,a Saritha Sekhar,b Sajitha Krishnan,c K. Venugopal,d and K.U. Natarajane,⁎Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain//Indian Heart J. 2015 Nov-Dec; 67(6): 538–542.Published online 2015 Oct 26. doi: 10.1016/j.ihj.2015.06.035
Wu A.H. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results / A.H. Wu, F. Wians, A. Jaffe // Am. Heart J. – 2013. – Vol. 165 (6). – P. 995-999.
